Navigation Links
VGX Pharmaceuticals' Novel HIV and Pandemic Influenza DNA Vaccine,Candidates Trigger Robust Immune Responses and Protection in,Pre-Clinical Models

MALAGA, Spain--(BUSINESS WIRE)--May 23, 2007 - VGX Pharmaceuticals' novel pandemic influenza vaccine candidates triggered protective immune responses in pre-clinical challenge studies, according to data presented for the first time today at the Third International Conference on DNA Vaccines in Malaga, Spain.

VGX scientists created four synthetic consensus DNA vaccines to protect against a lethal Vietnamese H5N1strain of avian influenza in mice. One of the vaccines resulted in complete protection of mice from death and illness of the challenge while 2 others had 60-80% protective effects. All of the vaccines were delivered using VGX's proprietary CELLECTRA(TM) DNA Delivery Device. CELLECTRA(TM) is a novel adaptive electroporation device developed by VGX. The avian flu data was presented by Dr. Ruxandra Draghia-Akli, VGX Vice President, Immune Therapeutics Research.

Separately at the opening plenary session, Professor David B. Weiner of the University of Pennsylvania, Conference Chairman and a Co-founder of VGX, presented new data showing extensive T-cell mediated immune responses to VGX's HIV vaccine candidates delivered with CELLECTRA(TM) in non-human primates. Most notably, the monkeys immunized with VGX vaccines displayed HIV-specific T cell responses as much as 10-20 fold greater than those reported in the literature using other vaccine modalities. Induction of high levels of T cell immune responses, especially the CD8+ Killer T cell responses, has long been thought to be important for developing a successful vaccine for HIV.

VGX plans to conduct further preclinical studies for both the HIV and Avian Flu vaccines, including the IND-enabling toxicology studies in 2007.

From the conference in Malaga, Spain, Dr. J. Joseph Kim, President and CEO of VGX, commented, "Our data demonstrates the potential of our DNA vaccine approaches in addressing these significant global health problems. We pla n to further collaborate with experts and leading organizations in the field in order to advance our promising clinical programs forward."

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecules and biologics product candidates for the treatment of infectious diseases, cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR(TM) for HIV infection and VGX-410C for chronic HCV infection, both of which are currently in Phase II clinical trials. In addition, Phase I clinical trials will be initiated in 2007 for VGX-150 for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX's research pipelines include new generation of DNA vaccines and therapeutics as well as CELLECTRA(TM), a proprietary DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Contact

VGX Pharmaceuticals
Kevin W. Rassas, 267-440-4208
Senior Vice President
Fax: 267-440-4242
Rassas@vgxp.com
www.vgxp.com


'"/>




Related medicine technology :

1. Faust Pharmaceuticals Phase IIa Results for Parkinsons Disease Presented at International Congress of Parkinsons Disease and Movement Disorders
2. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Executive Officer of the Company is scheduled to present on Tuesday, ... and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... YORK , April 19, 2017 The Mobile ... to showcase a healthy CAGR during the forecast period ... type in the global digital mobile X-Ray devices market, which ... Mn in 2017, expanding at a CAGR of 7% over ... absolute $ opportunity of more than US$ 100 Mn in ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... Association’s Outstanding Public Communication of Education Research Award. The award honors scholars exemplary ... communities. It recognizes a scholar who has demonstrated the capacity to deepen the ...
(Date:4/24/2017)... ... 2017 , ... Veteran Theresa James awoke to the sound of her newly ... “Healing Tears,” James depicts every parent’s worst nightmare, when her three children were violently ... and situations throughout my divorce,” James said. “After the death of my children, I ...
(Date:4/24/2017)... Waycross, Ga. (PRWEB) , ... April 24, 2017 ... ... and trusted advisor within the telehealth industry, announces the company’s VideoMedicine mobile platform ... primary care providers. Available 24 hours a day, Quick Care provides patients with ...
(Date:4/24/2017)... ... 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, was recently featured ... at the forefront of Gardant since it was founded in 1999. His drive and ... of more than 40 new senior living communities. With his leadership, Gardant has grown ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads all ... found any of them to be very practical. She wanted to write a guide/workbook ... changes in their health. It prompted her in writing “ A Clear Path to ...
Breaking Medicine News(10 mins):